AI assistant
BOSTON SCIENTIFIC CORP — Director's Dealing 2019
Jan 4, 2019
29821_dirs_2019-01-04_ce204fe2-08f8-4eb4-a3ed-a785231fce26.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BOSTON SCIENTIFIC CORP (BSX)
CIK: 0000885725
Period of Report: 2019-01-03
Reporting Person: Ballinger Kevin J. (EVP & Pres, Interven Cardio)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-01-03 | Common Stock | S | 2140.0000 | $34.2127 | Disposed | 82223.0000 | Direct |
| 2019-01-03 | Common Stock | S | 12600.0000 | $33.5507 | Disposed | 69623.0000 | Direct |
Footnotes
F1: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.
F2: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $34.10 to $34.29, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
F4: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $33.05 to $34.04, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.